www.rexahn.com
Rexahn’s goal is to be a world-class biopharmaceutical company developing and delivering novel cures for cancer and disorders of the central nervous system (CNS) to patients worldwide. Leveraging a powerful, multi-faceted discovery engine consisting of small signaling molecule discovery, computational modeling and nanotechnology-based drug targeting and delivery, we believe that we are well on our way to achieving our goal.
Articles
-
12/11/2010
Rexahn Pharmaceuticals: multiple drugs in development with blockbuster potential
As the story goes, after Dr. Chang Ahn witnessed his sister succumb to cancer he became determined to find a cure for the disease.
-
29/03/2010
Rexahn Pharmaceuticals discovery platform continues to churn out potential blockbuster compounds
Chang Ahn, the founder of Rexahn Pharmaceuticals, lost his sister to stomach cancer. This drove Dr. Ahn’s passion to find a cure, which eventually positioned Rexahn as a leading biopharmaceutical company
News
-
22/06/11
Rexahn completes enrollment for phase 2 antidepressant drug trial -
07/03/11
Rexahn Pharmaceuticals' CEO to become CSO; new CEO expected by September -
28/02/11
Rexahn Pharmaceuticals receives European patent for anti-cancer compounds -
20/01/11
Rexahn Pharmaceuticals sees Israel's Teva Pharmaceutical Industries boost shareholding -
20/12/10
Rexahn Pharmaceuticals issued Japanese patent for anti-cancer compound RX-0047 -
08/12/10
Rexahn Pharmaceuticals Presents Serdaxin Phase IIa Clinical Data at the American College of Neuropsychopharmacologists -
22/11/10
Rexahn Pharmaceuticals adds US patent to CNS treatment portfolio -
08/11/10
Rexahn Pharmaceuticals publishes anti-cancer compounds study in medical journal -
04/11/10
Rexahn Pharmaceuticals receives more than $800,000 in US govt grants for projects -
19/10/10
Rexahn Pharmaceuticals rallies on publication of new preclinical data for anti-cancer compounds
Recent Sector News
-
Dow suffers on Greece fears, Hewlett-Packard in focus
U.S. equity markets fell Wednesday afternoon on concerns that Greece could exit the euro as the region’s gather for an informal meeting.
-
Dow points lower ahead of eurozone meeting, Facebook, Dell in focus
U.S. equity markets looked set to open lower Wednesday morning ahead of a meeting of European Union leaders amid continued worries over the eurozone debt crisis.
-
Q1 gold demand underpinned by China, Central Banks and ETFs
Global gold demand in the first quarter of 2012 was 1,097.6 tonnes, down 5 percent from the high demand levels seen a year earlier, according to the World Gold Council.
-
Medgenics cleared by FDA to begin Phase IIb clinical trials for EPODURE; shares up
Biopharmaceutical company Medgenics (LON:MEDG, AMEX:MDGN) achieved a major milestone today - with clearance to begin a phase IIb trial of EPODURE to treat anaemia in kidney failure patients.
-
Facebook boosts public offering by 25%
Social network site Facebook Wednesday increased the size of its initial public offering by almost 25 per cent as it could raise as much as $16 billion on strong investor demand for its market debut.
-
Snipp plans ambitious growth as mobile marketing takes off
Mobile marketing company Snipp (CVE:SPN) (TSX.V:SPN), which recently listed on the TSX Venture Exchange, is now seeking a listing on the OTC exchange as it continues to grow in a space that is seeing more and more traction from companies looking to boost their marketing efforts.
What do others think of Rexahn Pharmaceuticals
Investors interested in Rexahn Pharmaceuticals recently viewed
-
Medgenics (AIM: MEDG) Developing "Biopump" technology for the treatment of chronic diseases -
Alliance Pharma (AIM: APH) Prescription branded medicines in the human medical and dental sectors -
e-Therapeutics plc (AIM: ETX) Systems Biology Drug Discovery -
Oxford Pharmascience (AIM: OXP) Developing proprietary delivery systems for medicines & supplements -
Tissue Regenix Group (AIM: TRX) Delivering regenerative solutions
